Research Topics
| Karen QuillenSummaryAffiliation: Boston University Country: USA Publications
| Collaborators
|
Detail Information
Publications
A practical strategy to reduce the risk of passive hemolysis by screening plateletpheresis donors for high-titer ABO antibodiesKaren Quillen
Department of Transfusion Medicine, NIH Clinical Center, Bethesda, Maryland, USA
Transfusion 51:92-6. 2011..Hemolytic transfusion reactions (HTRs) can occur from ABO-incompatible platelet (PLT) transfusions. After a series of cases at our institution, a procedure to screen all plateletpheresis donors for high-titer ABO antibodies was implemented...
Granulocyte transfusions in severe aplastic anemia: an eleven-year experienceKaren Quillen
Department of Transfusion Medicine, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, MD, USA
Haematologica 94:1661-8. 2009..Infections, particularly those caused by invasive fungi, are a major cause of death in patients with severe aplastic anemia. The purpose of this study was to analyze our experience with granulocyte transfusions in such patients...- Screening plateletpheresis donors for HLA antibodies on two high-throughput platforms and correlation with recipient outcomeKaren Quillen
Department of Transfusion Medicine, National Institutes of Health Clinical Center, Bethesda, Maryland 02118, USA
Transfusion 51:504-10. 2011.... - Ten-year follow-up of unrelated volunteer granulocyte donors who have received multiple cycles of granulocyte-colony-stimulating factor and dexamethasoneKaren Quillen
Department of Transfusion Medicine, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
Transfusion 49:513-8. 2009..The short-term side effects of G-CSF are well studied, but the potential long-term effects of repeated G-CSF stimulation in unrelated volunteer granulocyte donors have not been reported... - The determinants of granulocyte yield in 1198 granulocyte concentrates collected from unrelated volunteer donors mobilized with dexamethasone and granulocyte-colony-stimulating factor: a 13-year experienceKaren Quillen
Department of Transfusion Medicine, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
Transfusion 49:421-6. 2009.... - Prevalence of ceftriaxone-induced red blood cell antibodies in pediatric patients with sickle cell disease and human immunodeficiency virus infectionKaren Quillen
Department of Pathology and Laboratory Medicine, Boston Medical Center, Boston, MA 02118, USA
Pediatr Infect Dis J 27:357-8. 2008..The prevalence of anticeftriaxone antibody was 12.5% (8 of 64). Two of these 8 patients with the antibody experienced hemolysis; 1 case was fatal... - A second course of high-dose melphalan and auto-SCT for the treatment of relapsed AL amyloidosisK Quillen
Department of Medicine, Boston University Medical Center, Boston, MA 02118, USA
Bone Marrow Transplant 46:976-80. 2011..Three patients died of progressive disease at 1-2 years. In conclusion, one-third of patients with AL amyloidosis who relapse after HDM/SCT can achieve HCR with a second SCT... 
Quality improvement to decrease specimen mislabeling in transfusion medicineKaren Quillen
Department of Laboratory Medicine, Boston University Medical Center, Boston, Mass 02118, USA
Arch Pathol Lab Med 130:1196-8. 2006..Proper specimen identification and labeling is a critical preanalytic step in pretransfusion compatibility testing...- Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65David C Seldin
Section of Hematology Oncology, Boston University Medical Center, 650 Albany St, Boston, MA 02118, USA
Blood 108:3945-7. 2006.... - Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosisSaulius Girnius
Amyloid Treatment and Research Program, Boston University School of Medicine, Boston, MA 02118, USA
Ann Hematol 89:579-84. 2010..Hematologic relapses occurred in 60% of patients at a median of 1 year after HDM/SCT. In conclusion, HDM/SCT can prolong overall survival in patients with MM/AL who are eligible to receive it... - Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantationDavid C Seldin
Amyloid Treatment and Research Program, Department of Medicine, Boston University School of Medicine, Boston, MA, USA
Blood 104:1888-93. 2004..Thus, treatment of AL amyloidosis patients with HDM/SCT produces measurable and sustained improvements in quality of life, particularly in those patients who achieve hematologic CR... - Spontaneous rupture of the liver in a patient with systemic AL amyloidosis undergoing treatment with high-dose melphalan and autologous stem cell transplantation: a case report with literature reviewMartin Tam
Graduate Medical Sciences Division, Boston University School of Medicine, Boston, Massachusetts, USA
Amyloid 16:103-7. 2009..A literature review of spontaneous liver rupture in patients with amyloidosis is presented... - Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patientsMaria Teresa Cibeira
Amyloid Treatment and Research Program, Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA
Blood 118:4346-52. 2011..9 years, respectively. Thus, treatment of selected AL patients with HDM/SCT resulted in a high organ response rate and long OS, even for those patients who did not achieve CR... - Hepatic response after high-dose melphalan and stem cell transplantation in patients with AL amyloidosis associated liver diseaseSaulius Girnius
Department of Medicine, Boston University School of Medicine, Boston University School of Public Health, Boston, MA, USA
Haematologica 94:1029-32. 2009..In conclusion, hepatic disease improves in almost 2/3 patients treated with high-dose intravenous melphalan and autologous stem cell transplantation who have a complete or partial hematologic response to treatment... - Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantationVaishali Sanchorawala
Stem Cell Transplantation Program of the Section of Hematology Oncology, Boston University School of Medicine, Boston, MA 02118, USA
Blood 110:3561-3. 2007..001). In conclusion, HDM/SCT leads to durable remissions and prolonged survival, particularly for those patients who achieve a hematologic CR... - Probiotic-associated high-titer anti-B in a group A platelet donor as a cause of severe hemolytic transfusion reactionsJennifer Daniel-Johnson
Department of Transfusion Medicine, Warren G Magnuson Clinical Center, and the Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
Transfusion 49:1845-9. 2009..Reported cases have involved group O donors. Two cases of PLT-mediated HTRs associated with the same group A plateletpheresis component, collected from a donor taking high doses of probiotics are reported... - High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year studyMartha Skinner
Boston University School of Medicine, Boston, Massachusetts 02118, USA
Ann Intern Med 140:85-93. 2004..AL amyloidosis is a fatal disease resulting from tissue deposition of amyloid fibrils derived from monoclonal immunoglobulin light chains. Treatment with oral chemotherapy is minimally effective... - A massive transfusion protocol incorporating a higher FFP/RBC ratio is associated with decreased use of recombinant activated factor VII in trauma patientsJosenia N M Tan
Dept of Pathology and Laboratory Medicine, Boston University Medical Center, MA 02118, USA
Am J Clin Pathol 137:566-71. 2012..An MTP incorporating a higher FFP/RBC ratio of 1:1 to 1:2 is associated with decreased use of blood components and may obviate the need for rFVII... - Prevalence of RhD variants, confirmed by molecular genotyping, in a multiethnic prenatal populationDehua Wang
Department of Pathology and Laboratory Medicine, Boston Medical Center, Boston University School of Medicine, Boston, MA 02118, USA
Am J Clin Pathol 134:438-42. 2010..2% of our multiethnic population. Consideration of patients' ethnic background and close cooperation between pathologists and obstetric providers facilitate optimal prenatal care in these cases... - Effect of hydroxyurea on immature reticulocyte fraction in sickle cell anemiaRobert Bagdasaryan
Department of Pathology and Laboratory Medicine, Rhode Island Hospital, Providence, Rhode Island, USA
Lab Hematol 13:93-7. 2007..4), suggesting continuous bone marrow stimulation in SS-HU patients in response to tissue hypoxia. The possible underlying physiological mechanisms are discussed... - A novel sickle hemoglobin: hemoglobin S-south endHong-yuan Luo
Hemoglobin Diagnostic Reference Laboratory, Boston Medical Center, Boston, Massachusetts, USA
J Pediatr Hematol Oncol 26:773-6. 2004..Furthermore, the variant hemoglobin mimics Hb A on high-pressure liquid chromatography, and its identity is not easily diagnosed. A succinct review of variant sickle hemoglobins is also presented...